• AIM ImmunoTech reported positive mid-year interim progress from its Phase 2 DURIPANC study of Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer.
• Interim results have already been presented; the primary endpoint readout is scheduled for December 2026.
• The update supports continued development of the combination as a potential option for patients whose disease has not worsened after initial chemotherapy.
• The trial has enrolled its final patient, keeping the program on track for the planned endpoint evaluation.
• Management signaled planning for a pivotal Phase 3 trial pairing Ampligen with a PD-1 inhibitor, targeting survival and disease-control outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606080833PRIMZONEFULLFEED9733006) on June 08, 2026, and is solely responsible for the information contained therein.